Artiva Biotherapeutics Advances AlloNK in Refractory Rheumatoid Arthritis with Key 2026 Milestones
Event summary
- Artiva Biotherapeutics reported $108.0 million in cash, cash equivalents, and investments as of December 31, 2025, expected to fund operations into Q2 2027.
- Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in the first half of 2026.
- FDA interaction to discuss potential pivotal trial design for AlloNK expected in the first half of 2026.
- Strengthened board and executive leadership with deep immunology, commercial, and financial expertise.
- Reported a net loss of $83.9 million for the year ended December 31, 2025, compared to a net loss of $65.4 million for the year ended December 31, 2024.
The big picture
Artiva Biotherapeutics is positioning AlloNK as a potential first-in-class therapy for refractory rheumatoid arthritis, a market with significant unmet need. The company's strategic focus on outpatient feasibility and deep B-cell depletion could redefine treatment paradigms if clinical data and regulatory interactions are favorable. With a strengthened leadership team and a robust cash position, Artiva is poised to advance AlloNK through critical milestones in 2026.
What we're watching
- Clinical Data Impact
- How initial clinical response data for AlloNK in refractory RA will influence FDA discussions and potential pivotal trial design.
- Regulatory Pathway
- Whether Artiva can secure FDA alignment on a registrational trial design for AlloNK in refractory RA by mid-2026.
- Financial Runway
- The pace at which Artiva will need to secure additional funding to extend its cash runway beyond Q2 2027.
Related topics